Immunotherapy: An evolving paradigm in the treatment of advanced cervical cancer

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 20-38

  Eskander, Ramez N ^a   Tewari, Krishnansu S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical cancer; Checkpoint inhibitor; Chimeric T cell receptor antigen; Human papillomavirus; Immunotherapy; Therapeutic vaccine

Indexed keywords

ALPHA2B INTERFERON; AMOLIMOGENE BEPIPLASMID; BACTERIAL VACCINE; BACTERIAL VECTOR; BCG VACCINE; BISPECIFIC ANTIBODY; BISPECIFIC T CELL ENGAGER ANTIBODY; BLINATUMOMAB; CANCER VACCINE; CARBOPLATIN; CORTICOSTEROID; DENDRITIC CELL VACCINE; DNA VACCINE; NUCLEIC ACID; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; RNA VACCINE; SIPULEUCEL T; SMALLPOX VACCINE; T LYMPHOCYTE RECEPTOR; TOCILIZUMAB; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS VECTOR; WART VIRUS VACCINE; IMMUNOLOGIC FACTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SCREENING; CELL THERAPY; CHIMERA; CORTICOSTEROID THERAPY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HISTORY OF MEDICINE; HOSPITAL PATIENT; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; OVERALL SURVIVAL; PATHOGENICITY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; UTERINE CERVIX CANCER; VACCINIA VIRUS; WART VIRUS; WHOLE CELL; ADOPTIVE IMMUNOTHERAPY; FEMALE; IMMUNOTHERAPY; PROCEDURES; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

CANCER VACCINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84920855444     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.11.010     Document Type: Review

References (90)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
3. Eskander RN, Tewari KS. Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol. 2014;26:314-321.
4. Monk BJ, Tewari KS. Evidence-based therapy for recurrent cervical cancer. J Clin Oncol. 2014;32:2687-2690.
5. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899-903.
6. McGuire WP 3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7:1462-1468.
7. Fracasso PM, Blessing JA, Wolf J, et al. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2003;90:177-180.
8. Thigpen T, Blessing JA, Gallup DG, et al. Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1995;57:376-379.
9. Sutton GP, Blessing JA, Adcock L, et al. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs. 1989;7:341-343.
10. Look KY, Blessing JA, Levenback C, et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1998;70:334-338.
11. Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000;76:204-207.
12. Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000;77:446-449.
13. Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2001;19:1275-1278.
14. McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792-795.
15. Garcia AA, Blessing JA, Vaccarello L, Roman LD. Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2007;30:428-431.
16. Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;96:108-111.
17. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2002;20:1832-1837.
18. Long HJ III, Bundy BN, Grendys EC Jr., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633.
19. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
20. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-3119.
21. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
22. Tewari KS, Sill MW, Long HJ III, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734-743.
23. Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact, and toxicology. Future Med. In press.
24. Eskander RT, KS. Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol. 2014;6:280-292.
25. Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J. Gynecol Oncol. 2014;25:249-259.
26. Krill LS, Adelson JW, Randall LM, Bristow RE. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research: is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol. 2014;134:447-449.
27. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of highgrade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009;69:4407-4414.
28. Romanczuk H, Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A. 1992;89:3159-3163.
29. Howley PM, Munger K, Romanczuk H, et al. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp. 1991;22:239-248.
30. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480-489.
31. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529-564.
32. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol. 2003;81:106-113.
33. Su JH, Wu A, Scotney E, et al. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs. 2010;24:109-129.
34. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26:5315-5320.
35. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cellsurface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13:89-98.
36. Bermudez-Humaran LG, Langella P, Miyoshi A, et al. Montes de Oca-Luna R, et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol. 2002;68:917-922.
37. Pan ZK, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 1995;55:4776-4779.
38. Pan ZK, Ikonomidis G, Lazenby A, et al. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat Med. 1995;1:471-477.
39. Wallecha A, Carroll KD, Maciag PC, et al. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol. 2009;66:1-27.
40. Shahabi V, Reyes-Reyes M, Wallecha A, et al. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57:1301-1313.
41. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27:3975-3983.
42. Petit RG, Basu P. Advaxis Inc., Princeton, NJ; Chittaranjan National Cancer Institute, Kolkata, India. ADXS11-001 immunotherapy targeting HPV-E7: preliminary survival data from a P2 study in Indian women with recurrent/refractory cervical cancer. J Clin Oncol. 2013;31(Suppl): Abstract 5529.
43. Wallecha A, French C, Petit R, et al. Lm-LLO-Based Immunotherapies and HPV-Associated Disease. J Oncol. 2012;2012:542-851.
44. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol. 2014;32(Suppl 5): Abstract 5610.
45. Huh WK, Brady W, Moore KN, et al. A phase 2 study of liveattenuated listeria monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265). J Clin Oncol. 2014;32 (5 suppl): Abstract TPS5617.
46. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV- 18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002;8:3676-3685.
47. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 1996;347:1523-1527.
48. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitopecontaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242-2249.
49. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999;35:946-952.
50. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res. 2008;14:169-177.
51. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14:178-187.
52. Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007;106:558-566.
53. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol. 2007;106:453-460.
54. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother. 2004;53:642-650.
55. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004;23:172-181.
56. de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine. 2002;20:3456-3464.
57. Vici P, Mariani L, Pizzuti L, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res. 2014;33:29.
58. Van Doorslaer K, Reimers LL, Studentsov YY, et al. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol. 2010;116:208-212.
59. Tewari KS, Monk BJ. New strategies in cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res. 2014;20:5349-5358.
60. Matijevic M, Hedley ML, Urban RG, et al. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. Cell Immunol. 2011;270:62-69.
61. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103:317-326.
62. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Trans Med. 2012;4:155ra38.
63. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520-3526.
64. McKarney I. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. Issues Emerg Health Technol. 2007;101:1-4.
65. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003;129:521-530.
66. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol. 2008;82:1968-1979.
67. Zimmerman Z, Maniar T, Nagorsen D. Unleashing the clinical power of T cells: CD19/CD3 bispecific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy. Int Immunol. 2014 Sep 19. [Epub ahead of print].
68. Shi H, Sun M, Liu L, Wang Z. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer. 2014;13:219.
69. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 2014;257:127-144.
70. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257:107-126.
71. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med.. 2014;371:1507-1517.
72. Garfall AL, Fraietta JA, Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med. 2014;17:37-46.
73. Grupp SA, Maude SL, Shaw P, et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed. Refractory ALL. Blood. 2014. Abtsract 380.
74. Wickramasinghe D. Tumor and T cell engagement by BiTE. Discov Med. 2013;16:149-152.
75. Topp MS, Gokbuget N, Zugmaier G, et al. Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2014 Nov 10. [Epub ahead of print].
76. Rossi EA, Rossi DL, Cardillo TM, Chang CH, Goldenberg DM. Redirected T-cell killing of solid cancers targeted with an anti- CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-alpha. Mol Cancer Ther. 2014;13:2341-2351.
77. Hinrichs CS, Stevanovic S, Draper L, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol. 2014;32 (Suppl 5): Abstract LBA3008.
78. Rosenberg SA, Restifo NP, Yang JC. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
79. Lebbe C, et al. Presented at ESMO 2012; Poster Presentation 1116PD.
80. Mayor S. State-of-the-art treatment for advanced melanoma. Cancer World. 2011:e1-e20.
81. Vasaturo A, Di Blasio S, Peeters DG, et al. Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: AGame of Stop and Go. Front Immunol. 2013;4:417.
82. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733-1741.
83. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-1117.
84. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41-53.
85. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
86. Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloidderived suppressor cell differentiation. Cancer Immunol Res. 2013;1:256-268.
87. Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1-13.
88. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
89. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
90. Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76:233-247.